REGENXBIO Inc. (RGNX) Earnings History
Annual and quarterly earnings data from 2013 to 2024
Loading earnings history...
RGNX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
RGNX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 59.7% | -280.0% | -272.5% |
| 2023 | 58.8% | -297.1% | -292.0% |
| 2022 | 51.6% | -233.2% | -248.7% |
| 2021 | 89.0% | 34.0% | 27.2% |
| 2020 | 76.9% | -77.1% | -72.0% |
Download Data
Export RGNX earnings history in CSV or JSON format
Free sign-in required to download data
REGENXBIO Inc. (RGNX) Earnings Overview
As of May 8, 2026, REGENXBIO Inc. (RGNX) reported trailing twelve-month net income of -$178M, reflecting +23.8% year-over-year growth. The company earned $-3.44 per diluted share over the past four quarters, with a net profit margin of -272.5%.
Looking at the long-term picture, RGNX's historical earnings data spans multiple years. The company achieved its highest annual net income of $128M in fiscal 2021.
REGENXBIO Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SGMO (-$109M net income, -169.4% margin), RCKT (-$223M net income), KRYS ($225M net income, 52.6% margin), RGNX has room to improve margins relative to the peer group. Compare RGNX vs SGMO →
RGNX Earnings vs Peers
Earnings metrics vs comparable public companies
RGNX Historical Earnings Data (2013–2024)
12 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$227M | +13.8% | -$233M | $-4.59 | -272.5% | -280.0% |
| 2023 | -$263M | +6.0% | -$268M | $-6.02 | -292.0% | -297.1% |
| 2022 | -$280M | -319.3% | -$263M | $-6.50 | -248.7% | -233.2% |
| 2021 | $128M | +214.9% | $160M | $2.91 | 27.2% | 34.0% |
| 2020 | -$111M | -17.4% | -$119M | $-2.98 | -72.0% | -77.1% |
| 2019 | -$95M | -194.8% | -$149M | $-2.58 | -268.9% | -422.9% |
| 2018 | $100M | +236.6% | $88M | $2.73 | 45.7% | 40.3% |
| 2017 | -$73M | -16.2% | -$76M | $-2.45 | -704.0% | -730.2% |
| 2016 | -$63M | -176.0% | -$65M | $-2.38 | -1372.1% | -1423.8% |
| 2015 | -$23M | -469.8% | -$23M | $-2.49 | -300.6% | -304.9% |
See RGNX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RGNX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RGNX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRGNX — Frequently Asked Questions
Quick answers to the most common questions about buying RGNX stock.
Is RGNX growing earnings?
RGNX EPS is $-3.44, with earnings growth accelerating to +23.8%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-178M.
What are RGNX's profit margins?
REGENXBIO Inc. net margin is -272.5%, with operating margin at -280.0%. Below-average margins reflect competitive or cost pressures.
How consistent are RGNX's earnings?
RGNX earnings data spans 2013-2024. The accelerating earnings trend is +23.8% YoY. Historical data enables comparison across business cycles.